title: Innate adjuvant receptor Toll-like receptor 3 can promote breast cancer through cell surface.
abstract: Toll-like receptor 3 has been targeted in different cancers for adjuvant therapy. The ligand-mediated effects of TLR-3 on cancer cells are discordant. In the present work, we have addressed the hypothesis possibility of cell membrane-bound action of TLR-3 in breast cancer to justify its pro-tumor effect. TLR-3 was stimulated by Poly (I:C) on the surface of human breast cancer cells MCF-7 and MDA-MB-231 for up to 72 h. To check the cell survival and growth, thiazol blue tetrazolium bromide (MTT) assay, apoptosis assay, and cell cycle analysis were carried out. For changes in the metastatic properties, in vitro colony formation assay, scratch-wound healing assay and adhesion assay were also done. Using real-time PCR and immunocytochemistry, expression of E-cadherin, was studied. To determine the affect of cytoplasmic stimulation, Poly (I:C) was delivered with lipid transfection reagent. The results of the aforesaid experiments showed that there was a gradual increase of cellular survivability, growth, and metastasis after the cell surface stimulation of TLR-3 with Poly (I:C). Interestingly, E-cadherin expression was increased both at transcriptional and translational level. On the other hand, when Poly (I:C) was delivered in the cytoplasm by lipid transfecting medium, the cells survivability was decreased. For the first time, in the present work, we are convincingly reporting the functional evidence that TLR-3 induces cell survivability and metastasis through cell surface. The present work may help for the proper understanding of the adjuvant therapy of breast cancer.
authors.affiliation: Molecular Biology and Human Genetics Laboratory, Department of Zoology, The University of Burdwan, Golapbag Burdwan, 713104, West Bengal, India.
authors.forename: Banashree
authors.initials: B
authors.lastname: Bondhopadhyay
authors.forename: Anuradha
authors.initials: A
authors.lastname: Moirangthem
authors.forename: Anupam
authors.initials: A
authors.lastname: Basu
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D015820:Cadherins / Q000235:genetics; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism; D049109:Cell Proliferation / Q000235:genetics*; D017024:Chemotherapy, Adjuvant; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D061986:MCF-7 Cells; D011070:Poly I-C / Q000008:administration & dosage; D051196:Toll-Like Receptor 3 / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D015820:Cadherins; C495344:TLR3 protein, human; D051196:Toll-Like Receptor 3; D011070:Poly I-C